Small Molecules
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
126
NCT05268666
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Apr 8, 2022
Completion: Aug 31, 2025
Loading map...